Alvotech Advances in Biosimilar Market with Successful AVT03 Study
AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Novozymes and Chr. Hansen Complete Merger, Forming Novonesis
/in News/by Thomas GabrielczykDanish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.
2:1 for new genomic techniques
/in News/by Thomas GabrielczykFollowing the AGRI Committee of the European Parliament, the lead ENVI Committee has also agreed to relax the rules for the authorisation of NGTs.
Deregulation of new genomic techniques before decision
/in News/by Thomas GabrielczykAfter the EU Parliament's Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft […]
Amsilk partners with 21st.BIO
/in News/by Thomas GabrielczykAMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.
Onera Health raises US$32m in Series C round
/in News/by Thomas GabrielczykSleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.
Spexis sells antibiotics programme to Basilea
/in News/by Thomas GabrielczykMacrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Finnish Enifer Oy secures €12m grant to scale up
/in News/by Thomas GabrielczykMicrobial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.
Mogu Srl raises €11m to scale mycelium technology
/in News/by Thomas GabrielczykItalian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC)
Novo Nordisk Foundation in US$25m partnership with CARB-X
/in News/by Thomas GabrielczykNovo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.<br /><br />